Arnatar Therapeutics has launched with $52M in VC funding to create a dual-modality RNA platform. Its first target is Alagille syndrome (ALGS). Arnatar Details Innovative Nucleic Acid drug development Chinese origin, founded in 2022 using $14.45M from Apricot Capital. Operated in Stealth mode until Series A in 2025 HQ in San Diego, CASource: CapitalIQ.com Series … Continue reading Arnatar Tx Launches with $52M in Series A funding
Author: Bharat Kirthivasan
Why Biotech Deals Keep Coming with CVRs
When Concentra bought iTeos earlier this year, the headline number—$10.047 per share—looked underwhelming. In fact, it was at a slight discount to what the stock was trading at the day before. But buried in the fine print was something intriguing: a non‑transferable contingent value right (CVR) promising iTeos shareholders maybe more later if the company … Continue reading Why Biotech Deals Keep Coming with CVRs
FDA approvals in just 60 days?
The FDA has launched the Commissioner's National Priority Voucher (CNPV) program, offering 1-2 month reviews, so drug developers can get faster market access for products that align with national priorities. Some examples could be:1. Strengthening US employment in development & manufacturing2. Ensuring that clinical trials have robust US patient population3. Affordability of drug products by … Continue reading FDA approvals in just 60 days?
Novartis acquires Regulus Therapeutics for $1.7B
Novartis (NYS) completed on 25 June the $1.7B acquisition of Regulus Therapeutics (RGLS), a clinical-stage biotech company that will strengthen Novartis' renal disease pipeline. Regulus Therapeutics was formed in 2007 through a joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals with microRNA as the primary focus. Novartis announced its intent to acquire Regulus for $800M … Continue reading Novartis acquires Regulus Therapeutics for $1.7B
Biotech M&A – Three Trends to notice
Most biotech M&A coverage correctly highlights where capital is flowing, which therapeutic areas are hot, and which companies are poised to shape the future of medicine. For BD, corporate strategy, or investing, such information is useful. It gives context. It sets benchmarks. And it surfaces the big moves worth watching. But that's only part of … Continue reading Biotech M&A – Three Trends to notice
BK talks Biopharm 